Helus Pharma Reaffirmed at Buy as Phase 3 Depression Trial Nears Key Readout

H.C. Wainwright Maintains Bullish Stance on Depression Drug Developer H.C. Wainwright reiterated a Buy rating and $70 price target on Helus Pharma (NASDAQ:HELP) on Wednesday, positioning the biotech firm for a potential value inflection point as critical Phase 3 trial data approaches. The stock has surged 77% over the past year and currently trades at The post Helus Pharma Reaffirmed at Buy as…